VCEL
Vericel Corporation
$33.46
-4.75%
2026-05-08
About Vericel Corporation
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. The company was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
Key Fundamentals
P/E Ratio
78.33
Forward P/E
41.58
EPS (TTM)
$0.43
ROE
6.6%
Revenue Growth (YoY)
30.1%
Profit Margin
7.3%
Debt/Equity
26.51
Price/Book
4.81
Beta
1.23
Market Cap
$1.72B
Avg Volume (10D)
693K
Recent Breakout Signals
No recent breakout signals detected for VCEL.
Recent Price Range (60 Days)
60D High
$40.85
60D Low
$28.95
Avg Volume
626K
Latest Close
$33.46
Get breakout alerts for VCEL
Sign up for Breakout Scanner to receive daily notifications when VCEL triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Vericel Corporation (VCEL) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors VCEL daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. VCEL operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.